Newsroom

UNITE4TB’s PARADIGM4TB trial has reached another important milestone with the successful completion of recruitment to the second wave of its regimen-selection stage and has moved to the next stage of the study. This stage aims to identify the optimal treatment duration for the most promising tuberculosis (TB) regimens.

The latest UNITE4TB Newsletter is now available, bringing together key highlights from across the Consortium. 

On 15 June 2026, UNITE4TB held a webinar entitled “Antimicrobial Stewardship in Tuberculosis”, bringing together experts and stakeholders to discuss the critical role of stewardship in safeguarding tuberculosis (TB) treatment effectiveness. The webinar highlighted that drug-resistant TB remains an important challenge for global TB control, underscoring the urgent need to pres

The UNITE4TB Community Advisory Group (CAG) was pleased to take part in this year’s Annual Meeting in Munich, April 22-24, strengthening community-centred approaches across the consortium.

From April 22–24, 2026, the UNITE4TB Consortium gathered in Munich, Germany, for its Annual Meeting, bringing together partners from across the globe to share progress, exchange insights, and shape the next phase of tuberculosis (TB) research and development. 

Tuberculosis remains one of the world’s deadliest infectious diseases. Ending tuberculosis takes more than science — it takes collaboration, commitment, and shared expertise. 

UNITE4TB is proud to announce the initiation of STEP2C, a new Phase 2b clinical trial that forms part of the UNITE4TB clinical trial program.

The latest UNITE4TB Newsletter is now available, bringing together key highlights from across the Consortium as we close out 2025.

We are delighted to announce the conclusion of the UNITE4TB Expert Interview Series, featuring 11 thought-provoking conversations with leading voices from across the consortium.

The UNITE4TB Consortium has announced the start of recruitment for Wave 2 of the PARADIGM4TB trial, marking another important milestone in the effort to accelerate the development of novel tuberculosis (TB) treatment regimens.

PARADIGM4TB, the flagship trial of UNITE4TB, has reached an important milestone by successfully completing recruitment for the first stage of the study. This initial phase evaluated 10 experimental drug regimens alongside two control regimens. In total, PARADIGM4TB will test 14 drug regimens, aiming to accelerate the development of new treatments for tuberculosis (TB). 

We’re excited to launch a new video interview series featuring insights from experts across the UNITE4TB Consortium.

From 6 to 8 May 2025, the UNITE4TB Consortium convened in London for its Annual Meeting. Held across three venues — the Wellcome Collection, the Royal College of Physicians, and UCL’s MRC Clinical Trials Unit, the program spanned three focused days: Consortium Day, Scientific Day, and a Closed Investigator Meeting.

Three members of the UNITE4TB Consortium – Derek Sloan, Daniela Cirillo, and Hanif Esmail – share their insights in a new European Respiratory Society (ERS) video titled “Updates on the Management of Tuberculosis.”

The UNITE4TB Consortium recently published four new publications, one in the journal of Clinical Pharmacology & Therapeutics and three in Breathe, making continued strides to disseminate the work of the project.